CagriSema is investigational, not approved. Novo Nordisk submitted a New Drug Application to the FDA on 18 December 2025 for weight management in adults with obesity, or overweight with at least one weight-related condition, and the company has guided that a decision is anticipated by late 2026, but an application under review is not an authorization and nothing about that filing makes the product lawfully available now. The honest bottom line for anyone deciding whether to wait is that enrollment in a registered clinical trial is the only legitimate route to the studied product today.
CagriSema holds no marketing authorization from the FDA, the EMA, or any other national regulator, and its US New Drug Application, filed on 18 December 2025, carries a sponsor-projected decision in the fourth quarter of 2026.
No regulator has granted marketing authorization to the cagrilintide and semaglutide combination, and that list of agencies covers every major market: the FDA, the EMA, the UK MHRA, Health Canada, Japan's PMDA, and Australia's TGA. Investigational is a legal classification rather than a comment on how the data look, so a finished phase 3 program changes nothing about a product's status until an agency reviews the full dossier and issues an authorization.
Adding a second active ingredient creates a new product that regulators evaluate on its own evidence for efficacy, safety, dosing, and manufacturing quality, so semaglutide's existing approvals confer no legal status on the combination.
The submission rests on two trials, not on the head-to-head comparison that drew the most coverage. REDEFINE 1 and REDEFINE 2 are the phase 3 human evidence Novo Nordisk filed on, while REDEFINE 4, the open-label comparison against tirzepatide 15 mg, reported on 23 February 2026 and did not achieve its primary endpoint of non-inferiority.
| Criteria | REDEFINE 1 | REDEFINE 2 |
|---|---|---|
| Population | Obesity or overweight, no type 2 diabetes | 1,206 adults with type 2 diabetes |
| Average weight reduction | About 23 percent at 68 weeks | 15.7 percent among adherent participants |
| Result regardless of adherence | Reported against a much smaller placebo reduction | 13.7 percent |
| Role in the filing | Primary obesity evidence | Diabetes-population evidence |
In REDEFINE 4, CagriSema produced 23.0 percent weight loss against 25.5 percent for tirzepatide 15 mg among adherent participants, and 20.2 percent against 23.6 percent under the treatment-regimen estimand, missing the trial's non-inferiority endpoint.
The twelve-month figure quoted in coverage is really two clocks stacked on each other. The FDA takes roughly two months to decide whether a dossier is complete enough to accept, then runs a ten-month goal for acting on an application under standard review, and each stage has its own ways of stalling.
A first-cycle FDA review under standard timelines runs about twelve months from submission, roughly two months to accept the dossier plus a ten-month review goal, and approval still precedes real availability by several months of labelling, supply build, and payer negotiation.
No regulator rejected anything. The dates moved because the sponsor revised its own plan, and the public record of announcements shows where each revision landed. Guidance of this kind is issued to investors under disclosure rules, which makes it a forecast subject to revision rather than a promise to patients.
Novo Nordisk guided in March 2025 toward a first-quarter 2026 filing and submitted to the FDA on 18 December 2025 on the strength of REDEFINE 1 and REDEFINE 2, a schedule shaped by the sponsor's evidence and manufacturing-capacity choices rather than by any regulatory rejection.
Approval is not a single global event. A medicine can sit in pharmacies in one country while still under review in the next one over, because every regulator licenses on its own authority and most health systems run a separate funding decision after authorization.
Personal importation of an unauthorized medicine is unlawful in most jurisdictions and the goods can be seized, and the cross-border supply chains serving that demand are where counterfeit and mislabelled product circulates.
One lawful route exists in practice, and it is participation in a registered study. Everything else on offer, from a clinic willing to write a prescription to a pharmacy willing to compound a copy, sits outside the rules, since a valid prescription requires a product with marketing authorization and US compounding law is built around approved drug substances.
Enrollment in a registered clinical trial is the only route that lawfully supplies the actual investigational combination, with the study drug and study-related assessments provided at no cost to the participant.
Anything sold as CagriSema outside a clinical trial is not the product the trial results describe: no agency has assessed its identity, purity, potency, sterility, or stability, no inspector has seen the site that made it, and no verified chain of custody connects that site to the buyer. The reported efficacy attaches to a specific, quality-controlled formulation given under supervision, and it does not transfer to an unverified copy.
Products marketed online as CagriSema have passed no regulator's review of identity, purity, potency, or sterility, so the REDEFINE efficacy figures cannot be attributed to them at all.
A first label follows the populations that were actually studied, which points to chronic weight management in adults with obesity, or overweight plus at least one weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity. Less settled is the diabetes population: a dedicated trial enrolled it, but whether that becomes a weight indication in people with diabetes or a glycaemic indication depends on which endpoints the submission leads with, and the two are judged on different measures. Initial labels also run narrow at the edges, with children and adolescents, pregnant and breastfeeding people, and, given the semaglutide component, a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 expected to sit outside them.
| Criteria | Weight indication | Glycaemic indication |
|---|---|---|
| Judged mainly on | Percentage body weight change | HbA1c |
| Population studied | Obesity, or overweight plus a comorbidity | Adults with type 2 diabetes |
| Conventional eligibility | BMI 30 or above, or 27 with a comorbidity | Diagnosis-based |
| Likelihood in a first label | Expected | Endpoint-dependent, unsettled |
Eligibility in this class conventionally runs at a BMI of 30 or above, or 27 or above with a condition such as hypertension, dyslipidaemia, obstructive sleep apnoea, or established cardiovascular disease.
Approved options already reach into the same efficacy range the investigational combination reported. Semaglutide 2.4 mg weekly averaged roughly 15 percent weight reduction in its pivotal trials and tirzepatide reached the low twenties at the highest dose, which puts CagriSema's reported 23 percent in the same broad territory rather than in a category of its own.
Documented tolerance to a GLP-1 therapy, a recorded response, and payer approval already on file generally make a later move to a newer agent easier rather than harder.
Educational use only. This article describes what the published scientific and clinical literature reports about CagriSema. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
